In Q4, revenue will be higher than Q3 vimovo which offset some of the low income, and then there will be $1.88 M per quarter of interest payment instead of $3.6 M. Now add $2 to $3 M of net income from Vimovo in Q4 to above saving. Although HZNP is hiring 112 new salesmen but they are mostly on commission plus a base salary. At high end, if each of them cost $100k per year then the cost will be $2.8 M per quarter (not all will be paid fully in Q4).
So, supposed $2 M net increase in sale of DUEXIS and LODOTRA/RYOS, $2 M net from Vimovo and $2 M in interest saving, minus $2.8 M of new expenses, HZNP may go positive in Q4.
This option price is much higher than $5.36, the blood price that bankers paid plus earning 5% interest.
May be, HZNP is thinking to do another note to buyback and replace Nov 18 note.
A few blocks of shares were sold around $6.75 and some lucky investors grabbed them. I think, those blocks were warreat s from 2012 or earlier deals.
POZN has no product to sell but it is getting some small royalties. GSK used to sell Treximet for POZN but POZN sold its royalties to an investor for $75 M and a small royalty. It seems that POZN tries to cash in whatever it has. Now, most of cash is handed to its investors and insiders. It does not sound right to me.
You right about HZNP technical.
I think couterparties have an agenda too. They try to keep the stock under $6.97 as much as they can. $6.97 is 130% of $5.36, a price that makes conversion possible if it happens 20 of 30 trading days.
Of course, it is early to think about this subject since conversion is out of limit until June 2014.
POZN is getting rid of its cash, the cash that a small cap companies hardly can get. Probably, one reason is POZN insiders who own 22% of the company. I did some DD a weak ago and decided that it is not a good investment although the numbers may look good. I prefer HZNP over POZN and there is no chance of merging since HZNP already negociated Vimovo instead of merger.
There was an order over 100k shares to sell and the seller tried a few prices but eventually sold it down around 6.75. Hope to see some rebound from this point on.
Probably, some traders are cashing in past few days. That is the most reason for slowdown in HZNP momentum. They may be happy for their recent gain but investors with a long view wait for future since HZNP has a long way to go and this is just the start of a long journey.
Most small or startup pharmaceutical companies are taking huge risk to develop one drug and wait to see if FDA approves it. Then they deal with commercializing that one drug, the area they are not familiar and spends money to learn.
Well, HZNP is a company with 3 drugs and conting for more and most importantly it knows how to sell them.
I was not involve in the last run to $8 but I am now. $30 target is possible but I go one step at the time. I see a price around $12 in Feb 2014 when company announces Q4 and update 2014-2015 income.
What do you think?
Of course, it may change as the company acquires more products.
Based on this income, the target should be at $12.50 minimum.
Today is the best opportunity for me and others to load at these low prices as they last.
What does it mean? Is it the case that an assigned hedge fund short above this price to push the price under $6.71?
It is at current prices because some analysts put negative spin on CRUS great report and outlook to help their hedge funds friends and bosses. Hedge funds went wrong when they shorted CRUS in hope to cash in big time. They are doing some deals with some analysts to keep CRUS done in this case to cover their shorts that went wrong direction. Selling any share of CRUS is helping those hedge funds to cover their short position.
Robert cannot downgrade anymore although investors are laughing at him for his BS.
This ids from chipwork
"Other chips of interest include 16GB of Toshiba NAND Flash (yellow) and Apple's 338S1116 Cirrus Audio Codec (black), which iFixit says they also found in the iPhone 5c. For a full listing of all the chips, check out iFixit's teardown, which also includes 55 photos detailing the entire process."
Shame on manipulators.
This is not an opinion but is purposely twisting words and lying to benefit.
iPad air has a CRUS chip as identified by chipwork but Barclay's analyst is lying to investor when he is saying that there is no CRUS audio chip.
Robert and his company are subjet to be sued by investors since he is doing it purposely to manipulate the stock.